Eli Lilly and Company LLY Stock
Eli Lilly and Company Price Chart
Eli Lilly and Company LLY Financial and Trading Overview
- Eli Lilly and Company Price Chart
- Eli Lilly and Company LLY Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of Eli Lilly and Company
- Q&A For Eli Lilly and Company Stock
|Eli Lilly and Company stock price||584.04 USD|
|Previous Close||610.5 USD|
|Bid||0 USD x 800|
|Ask||0 USD x 800|
|Day's Range||602.56 - 629.97 USD|
|52 Week Range||309.2 - 629.97 USD|
|Avg. Volume||2.96M USD|
|Market Cap||578.31B USD|
|Beta (5Y Monthly)||0.331|
|PE Ratio (TTM)||84.72879|
|EPS (TTM)||5.55 USD|
|Forward Dividend & Yield||4.52 (0.73%)|
|Ex-Dividend Date||August 14, 2023|
|1y Target Est||587.74 USD|
LLY Valuation Measures
|Enterprise Value||563.95B USD|
|PEG Ratio (5 yr expected)||2.3|
Eli Lilly and Company Stock Price History
|Beta (5Y Monthly)||0.331|
|S&P500 52-Week Change||N/A|
|52 Week High||629.97 USD|
|52 Week Low||309.2 USD|
|50-Day Moving Average||554.17 USD|
|200-Day Moving Average||430.75 USD|
LLY Share Statistics
|Avg. Volume (3 month)||2.96M USD|
|Avg. Daily Volume (10-Days)||3.76M USD|
|% Held by Insiders||0.15%|
|% Held by Institutions||83.98%|
|Short % of Float||0.70%|
|Short % of Shares Outstanding||0.59%|
Dividends & Splits
|Trailing Annual Dividend Rate||4.22|
|Trailing Annual Dividend Yield||0.69%|
|5 Year Average Dividend Yield||157.00%|
|Last Split Factor||2:1|
|Fiscal Year Ends||December 31, 2022|
|Most Recent Quarter (mrq)||June 30, 2023|
|Next Fiscal Year End||December 31, 2023|
|Operating Margin (ttm)||28.13%|
|Return on Assets (ttm)||10.18%|
|Return on Equity (ttm)||65.60%|
|Revenue (ttm)||29.52B USD|
|Revenue Per Share (ttm)||32.76 USD|
|Quarterly Revenue Growth (yoy)||28.10%|
|Gross Profit (ttm)||21.91B USD|
|Net Income Avi to Common (ttm)||6.5B USD|
|Diluted EPS (ttm)||7.19|
|Quarterly Earnings Growth (yoy)||85.09%|
|Total Cash (mrq)||2.94B USD|
|Total Cash Per Share (mrq)||3.27 USD|
|Total Debt (mrq)||18.95B USD|
|Total Debt/Equity (mrq)||170 USD|
|Current Ratio (mrq)||1.128|
|Book Value Per Share (mrq)||12.303|
Cash Flow Statement
|Operating Cash Flow (ttm)||5.74B USD|
|Levered Free Cash Flow (ttm)||5.06B USD|
Profile of Eli Lilly and Company
|Address||Lilly Corporate Center|
|Phone||317 276 2000|
|Full Time Employees||39000|
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Q&A For Eli Lilly and Company Stock
What is a current LLY stock price?
Eli Lilly and Company LLY stock price today per share is 584.04 USD.
How to purchase Eli Lilly and Company stock?
You can buy LLY shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eli Lilly and Company?
The stock symbol or ticker of Eli Lilly and Company is LLY.
Which industry does the Eli Lilly and Company company belong to?
The Eli Lilly and Company industry is Drug Manufacturers-General.
How many shares does Eli Lilly and Company have in circulation?
The max supply of Eli Lilly and Company shares is 949.31M.
What is Eli Lilly and Company Price to Earnings Ratio (PE Ratio)?
Eli Lilly and Company PE Ratio is 105.23242000 now.
What was Eli Lilly and Company earnings per share over the trailing 12 months (TTM)?
Eli Lilly and Company EPS is 5.55 USD over the trailing 12 months.
Which sector does the Eli Lilly and Company company belong to?
The Eli Lilly and Company sector is Healthcare.
Eli Lilly and Company LLY included in indexes
|Name Name||Price Price||
7d chart 24h% & 7d
|VOL Volume||24h low||24h high||Volume|